Clinical Trial Enrichment Could Require Post-Market Studies, Labeling To Address Shortcomings

FDA’s guidance on clinical trial enrichment notes that a lack of information on patients without the enrichment characteristic may result in Phase IV studies to characterize a drug’s safety and efficacy in a broader population.